key: cord-0897941-lkl40tcu
authors: Yamamoto, Shohei; Mizoue, Tetsuya; Tanaka, Akihito; Oshiro, Yusuke; Inamura, Natsumi; Konishi, Maki; Ozeki, Mitsuru; Miyo, Kengo; Sugiura, Wataru; Sugiyama, Haruhito; Ohmagari, Norio
title: Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
date: 2022-04-12
journal: Obesity (Silver Spring)
DOI: 10.1002/oby.23417
sha: 2c474baa2093ee552b1102e5b046840ef3ab6bfe
doc_id: 897941
cord_uid: lkl40tcu

OBJECTIVE: This study investigated the sex‐associated difference in the impact of obesity on antibody response to a COVID‐19 vaccine. METHODS: This study included 2,435 health care workers who received two doses of the BioNTech, Pfizer (BNT162b2) vaccine and participated in a serological survey, during which they were tested for anti‐SARS‐CoV‐2 spike immunoglobin G (IgG) antibodies and asked for information on height, weight, and vaccination history via a questionnaire. Multivariable linear regression analysis was used to estimate the geometric mean titers (GMT) of antibodies for each sex and BMI category. RESULTS: The relationship between BMI and anti‐SARS‐CoV‐2 spike IgG titers markedly differed by sex (p value for interaction = 0.04). Spike IgG antibody titers tended to decrease with increasing BMI in men (p value for trend = 0.03); GMT (95% CI) were 6,093 (4,874‐7,618) and 4,655 (3,795‐5,708) for BMI < 18.5 and ≥30 kg/m(2), respectively. In contrast, spike IgG antibody titers did not significantly differ across BMI categories in women (p value for for trend = 0.62); GMT (95% CI) were 6,171 (5,714‐6,665) and 5,506 (4,404‐6,883) for BMI <18.5 and ≥30, respectively. CONCLUSIONS: Higher BMI was associated with lower titers of SARS‐CoV‐2 spike antibodies in men, but not in women, suggesting the need for careful monitoring of vaccine efficacy in men with obesity, who are at high risk of severe COVID‐19 outcomes.

Obesity is a major risk factor for morbidity and mortality in patients with COVID-19 (1) . Given the adverse effect of excess adipose tissue on the immune system (2) , obesity may interfere with the production of vaccine-specific antibodies. In clinical trials on the mRNA-based vaccine against SARS-CoV-2, vaccine recipients had a markedly lower risk of COVID-19 irrespective of obesity status (3) . However, a more recent observational study of 1.6 million people in Israel showed that vaccine efficacy (VE) was slightly lower among those with obesity than the total population (4) .

The evidence regarding the association between BMI and vaccine-induced antibody titers is limited and inconsistent (5) (6) (7) .

Given the sex difference in the distribution and function of adipocytes (8) , the inconsistency among previous studies could be ascribed, at least in part, to the lack of consideration of sex. Here, we investigate the sex-associated difference between BMI and SARS-CoV-2 antibodies among 2,435 health care workers who received two doses of the BioNTech, Pfizer (BNT162b2) vaccine. We hypothesize that higher BMI is associated with lower antibody titers in men only.

We launched a repeat serological survey in July 2020 to monitor the spread of SARS-CoV-2 infection among the staff of the National Center for Global Health and Medicine (NCGM; Tokyo, Japan), which has accepted a large number of COVID-19 inpatients. As of October 2021, we have completed three surveys, in each of which we measured anti-SARS-CoV-2 nucleocapsid (all surveys) and spike (from the second survey onward) protein antibodies. The details of the study design are available elsewhere (9) . For the present analysis, we used the data of the third survey (June 2021), 2 months after the in-house vaccination program (COVID-19 mRNA-lipid nanoparticle BNT162b2; BioNTech, Pfizer [BioNTech SE, Mainz, Germany; Pfizer Inc., New York, New York]). Of the 3,072 workers invited, a total of 2,779 (90%) participated. Of these, we included 2,514 staff who had received two doses of the vaccine. Of these, we excluded those who attended the survey within 14 days of the second vaccination (n = 5) and those who lacked data on height or weight (n = 74), leaving 2,435 participants for analysis. Written informed consent was obtained from each participant. The study procedure was approved by the NCGM ethics committee.

Participants were asked to donate venous blood. Data on height, We converted antibody titers into a log scale before analysis. We ran linear regression modeling to test the interaction between BMI and sex and estimate the ratio of means and the means of IgG titers for each sex and BMI category. Independent variables included BMI category, sex, the interaction term between BMI category and sex, age (continuous), days after the second vaccination (continuous), and history of COVID-19. We back-transformed the estimated values to present the ratios of means and geometric mean titers (GMT). We tested the trend of the association between BMI and antibody titers while assigning one through five to the increasing BMI categories.

We repeated the analyses using other BMI classifications recommended by WHO for Asian individuals (11) and in general (12) . To visualize the association between BMI and the predicted GMT of spike IgG antibodies, we ran the model while treating BMI (continuous) as a cubic polynomial (i.e., terms of BMI, BMI 2 , and BMI 3 ). Statistical significance was set at p < 0.05 for trend and p < 0.1 for interaction tests. Statistical analyses were conducted using Stata version 17.0 (StataCorp LLC, College Station, Texas).

The median age was 36.6 years (interquartile range [IQR]: 27.6-47.6), 70% of participants were women, 0.5% had a history of COVID-19, and the median interval between the second vaccination and blood sampling was 64 days (range: 15-103 days). Major occupations

What is already known?

► Obesity can downregulate immune response, but epidemiological evidence regarding the impact of obesity on COVID-19 vaccine-induced antibody production and its gender difference is scarce.

► A higher BMI was associated with lower levels of anti-SARS-CoV-2 spike immunoglobin G antibodies in male, but not female, vaccine recipients.

► Future studies on vaccine efficacy should pay attention to the sex-associated difference in the impact of obesity on the immune response to a COVID-19 vaccine.

included nurses (38.6%), doctors (17.7%), allied health care professionals (13.6%), and administrative staff (9.4%; Table 1 ). All participants were positive for SARS-CoV-2 spike antibodies, with a median of 6,063 AU/mL (IQR: 3,620-9,919).

There was a significant interaction between BMI category and sex (p value for interaction = 0.04; Table 2 ). In men, SARS-CoV-2 spike antibody titers progressively decreased with increasing BMI (p value for trend = 0.03), and adjusted geometric means (95% CI) were 6,093 (4,874-7,618) and 4,655 (3,795-5,708) for BMI < 18.5 and ≥30, respectively. In women, antibody titers did not significantly differ across BMI categories (p value for trend = 0.62), and adjusted geometric means (95% CI) were 6,171 (5,714-6,665) and 5,506 (4,404-6,883) for BMI < 18.5 and ≥30, respectively. Men with BMI < 18.5 had antibody titers similar to that of women in the same Information Tables S1-S2 ). In cubic spline regression analysis, GMT of antibody titers decreased linearly with increasing BMI in men, whereas no association was observed in women (p value for interaction = 0.03; Figure 1 ).

In the present study among health care workers who received two doses of the BNT162b2 vaccine, all participants were seropositive irrespective of BMI, and most of them had high titers of SARS-CoV-2 spike IgG antibodies. As hypothesized, there was a marked sex difference in the association between BMI and SARS-CoV-2 spike IgG antibody titers, with a significant inverse association being observed in men, but not in women. To the best of our knowledge, this is the first study to associate SARS-CoV-2 vaccine-induced immune response with adiposity in a sex-specific manner.

The lower antibody titers in men with obesity may be attributed to their adipose distribution. Compared with women with obesity, men with obesity are more likely to have greater visceral adipose tissue, which dysregulates the production of adipocytokines (8) . With increasing amounts of visceral adipose tissue, leptin, tumor necrosis factor α (TNFα), and interleukin (IL)-6 are overproduced, whereas adiponectin decreases (2) . Such imbalance of the adipocytokine profile can cause low-grade chronic inflammation, which can induce B cell immunosenescence and interfere with antibody production after vaccination (13) .

In contrast, antibody titers did not significantly differ across BMI categories in women. Given that 82% of female participants in the present study were under the age of 50 years, this finding could be ascribed, at least in part, to the effect of estrogen and progesterone on the regulation of adipose tissue distribution, adipogenesis, and adipocyte metabolism and production (8) . Owing to these hormones, women have less visceral adipose tissue, greater brown adipose tissue, and higher circulating adiponectin concentrations compared with men (8), all of which have been suggested to suppress chronic inflammation and activate the immune system (2, 14) .

We found that men with obesity had modestly (11%-13%) lower 

We thank Haruka Osawa for her contribution to data collection and the staff of the Laboratory Testing Department for their contribution to measuring antibody testing.

Antibody assay reagent was provided by Abbott Japan Co., Ltd (Tokyo, Japan). The authors declared no other conflict of interest. 

https://orcid.org/0000-0001-6503-8577

Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships

Obesity, inflammation and the immune system

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: findings from a large observational study in Israel

The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Confounding factors influencing the kinetics and magnitude of serological response following administration of

Sex differences in human adipose tissues -the biology of pear shape

COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study

World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment

Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

Obesity: preventing and managing the global epidemic

Adipose tissue inflammation induces B cell inflammation and decreases B cell function in aging

Obesity alters B cell and macrophage populations in brown adipose tissue

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine